Science Publishing Group

Laekna Releases 2023 ESG Report

Retrieved on: 
Lundi, avril 29, 2024
Organization, HKEX, Social, Person, Book, PCC, Female, Patient safety, Patent, Patient, ESG, GHG, Welfare, Workforce, Ethics, Growth, Science Publishing Group, Pharmaceutical industry

SHANGHAI and WARREN, N.J., April 29, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, released its 2023 Environmental, Social and Governance (ESG) report since its listing on the HKEX on June 29, 2023.

Key Points: 
  • SHANGHAI and WARREN, N.J., April 29, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, released its 2023 Environmental, Social and Governance (ESG) report since its listing on the HKEX on June 29, 2023.
  • Laekna strives for sustainable growth and ESG excellence through commitments to long termism.
  • In 2023, the company has crafted a comprehensive five-year ESG plan based on five pillars: Legitimate, Innovation, Green, Health and Talent (LIGHT).
  • Please visit: https://en.laekna.com/upload/2024-04/171412286459372700.pdf to find Laekna's 2023 Environmental, Social and Governance Report.

Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers

Retrieved on: 
Jeudi, avril 18, 2024
FDA, University, Mouse, Biochemistry, Lab, Science Publishing Group, Unique, Identification, Research, Autophagy, Molecular biology, WNK1, Pediatrics, Plasma protein binding, Narendran, PV-10, Pharmaceutical industry

KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research by the University of Calgary on oral administration of Provectus’s pharmaceutical-grade rose bengal for the treatments of solid tumor cancers were published in the open access journal of oncology Cancers.

Key Points: 
  • KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research by the University of Calgary on oral administration of Provectus’s pharmaceutical-grade rose bengal for the treatments of solid tumor cancers were published in the open access journal of oncology Cancers.
  • The Narendran Lab provided preclinical proof-of-concept data supporting the efficacy of Provectus’s rose bengal in a panel of adult solid tumors.
  • The Lab identified that the Company’s rose bengal downregulated WNK1 and Wnt signaling.
  • In mice, the Narendran Lab also confirmed the clinical utility of Provectus’s rose bengal by intratumoral (aka intralesional) administration and demonstrated potential utility by oral administration.

Nodexus Adds Flow Cytometry Leaders to Scientific Advisory Board

Retrieved on: 
Mercredi, avril 10, 2024
Oncology, Health, Health Technology, Research, Science, Pharmaceutical, Biotechnology, Breast cancer, Science Publishing Group, Immortalised cell line, University, International Society, ISAC, Jonni, SAB, CRISPR, Cell biology, Hospital, Seminal vesicles, Medical laboratory, Doctor of Philosophy, Pathology, Protein engineering, Therapy, New York Blood Center, Chairperson, Synthetic biology, Cardiovascular disease, Malignancy, Assistant, Inc., NX, HIV, Biomarker, Associate, SICS, AAPS, Flow cytometry

Nodexus Inc., a leader in automated benchtop single-cell characterization and microfluidic isolation technologies, today announced that three leading experts in cytometry sciences, pathology, and cancer biology have joined its Scientific Advisory Board (SAB).

Key Points: 
  • Nodexus Inc., a leader in automated benchtop single-cell characterization and microfluidic isolation technologies, today announced that three leading experts in cytometry sciences, pathology, and cancer biology have joined its Scientific Advisory Board (SAB).
  • The Nodexus SAB is chaired by Professor Jonni Moore, PhD, one of the world’s leading experts in flow cytometry, laboratory medicine, and cellular immunology.
  • He is a founding member of the Southern California Flow Cytometry Association (SoCal Flow) and the American Association of Pharmaceutical Scientists (AAPS) PharmaFlow Working Group.
  • “I’m extremely pleased to serve as the Chairperson of Nodexus’ Scientific Advisory Board,” said Dr. Moore.

Dr. J. Mark Tuthill Joins Gestalt Diagnostics' Strategic Advisory Board

Retrieved on: 
Vendredi, avril 26, 2024
Education, Science Publishing Group, Informatics, Henry Ford Health, Learning, Advisory board, Medical laboratory, Research, Pathology, API, Digital, Marie Cassidy, Computer, Patient, Henry Ford

SPOKANE, Wash., April 26, 2024 /PRNewswire/ -- Gestalt Diagnostics has added healthcare industry expert, Dr. J. Mark Tuthill, to serve on Gestalt's Advisory Board. He will be joining Gestalt's distinguished Advisory Board of pathologists contributing to oversight and active input of development initiatives as they relate to the functionality and usability of solutions in clinical practice, education, and research.

Key Points: 
  • Gestalt's Advisory Board guides the development of Gestalt's digital pathology platform, PathFlow® – made by pathologists for pathologists
    SPOKANE, Wash., April 26, 2024 /PRNewswire/ -- Gestalt Diagnostics has added healthcare industry expert, Dr. J.
  • Mark Tuthill, to serve on Gestalt's Advisory Board.
  • Dr. Tuthill is the Division Head of Pathology Informatics and Pathology Informatics Fellowship Director at Henry Ford Health where his specialties include both pathology and clinical informatics.
  • Dr. Tuthill states, "I am honored to be invited to serve on the Gestalt Strategic Advisory Board.

CHOP Researchers Discover Underlying Biology Behind Fontan-Associated Liver Disease

Retrieved on: 
Mercredi, avril 24, 2024
Online, Science Publishing Group, Fontan procedure, Patient, Cell, Hepatocyte, Liver disease, Inferior vena cava, Science Translational Medicine, Hope, NIH, Hospital, Blood, Tissue, Robert, CHOP, Agent handling, Heart, Wellness, MD, RNA, Medical laboratory, Doctor of Philosophy, SVRF, Activity, Survivor, Disease, Pathology, Ventricular septal defect, Fibrosis, Stasi, FC, Assistant, Biology, Children's Hospital of Philadelphia, Quality of life, Scar, Defense, Pharmaceutical industry

PHILADELPHIA, April 24, 2024 /PRNewswire/ -- As patients with congenital heart diseases live longer, researchers are attempting to understand some of the other complications they may face as they age. In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD).

Key Points: 
  • In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD).
  • The Fontan operation is the current standard of care for single-ventricle congenital heart disease.
  • As more patients undergo the Fontan surgery for single-ventricle congenital heart disease, FALD has become a more recognized problem.
  • Little information exists on FALD, yet it is distinct from other forms of liver disease, which is why researchers at CHOP wanted to understand the basic biology that could lead to better treatment options and improve these patients' quality of life.

Scopio Labs Receives Groundbreaking FDA Clearance for First-Ever Digital Bone Marrow Aspirate Application

Retrieved on: 
Mercredi, avril 17, 2024
FDA, Science Publishing Group, University, Bone marrow, TEL, Cell, Food, AI, De novo, Prevalence, Medical laboratory, X100, Pathology, BMA, Patient, DSS, Malignancy, Health, Cancer, Medical device

TEL AVIV, Israel , April 17, 2024 /PRNewswire/ -- Scopio Labs, developer of Full-Field Digital Cell Morphology™ imaging and analysis platforms and a recognized leader in digital morphology, today announced that it has been granted De Novo clearance by the U.S. Food and Drug Administration (FDA) for its Full-Field Bone Marrow Aspirate™ (FF-BMA) Application. This marks a pivotal moment, establishing a new regulatory category for all-digital bone marrow aspirate analysis software.

Key Points: 
  • This marks a pivotal moment, establishing a new regulatory category for all-digital bone marrow aspirate analysis software.
  • Bone marrow cytology, the microscopic analysis of cells in bone marrow samples, remains a crucial diagnostic tool for a wide range of blood disorders.
  • Bone marrow aspirate (BMA) plays a vital role in diagnosing these and other hematologic conditions, both malignant and benign.
  • For a comprehensive overview of Scopio Labs' Full-Field Digital Cell Morphology™ solutions, including the FF-BMA Application, please contact us.

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

Retrieved on: 
Mardi, février 27, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Bangladesh Technical Education Board, Takeda Pharmaceutical Company, MPM, Schering-Plough, Science Publishing Group, Hoechst AG, Research and development, NIH, Moderna, PureTech Health, Drug development, Bristol Myers Squibb, Doctor of Philosophy, Renegade, University, Partner, RNA, Therapy, Patient, Protein, Takeda Oncology, Development, Immune system, Pharmaceutical industry

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.

Key Points: 
  • ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.
  • “Joe is a pioneering scientist and drug development expert who brings to ReNAgade more than four decades of experience in oncology and immunology,” said Amit D. Munshi, Chief Executive Officer of ReNAgade.
  • Before joining PureTech, he oversaw all aspects of research and development for Moderna Therapeutics as President of Research & Development and Chief Scientific Officer.
  • Previously, he was Chief Scientific Officer at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company.

Arcadia University Announces New Academic Programs for Fall 2024

Retrieved on: 
Jeudi, février 29, 2024
Science Publishing Group, Arcadia University, Public health, Leadership studies, Faculty, News, Behavior, Student, Nursing

Arcadia also is proud to offer, beginning in fall 2024, a minor in Japanese; master's degree programs in Rehabilitation Science and Public Health (4+1 program), and certificates in Health Equity; Social, Emotional, and Behavioral Wellbeing; and Organizational Leadership.

Key Points: 
  • Arcadia also is proud to offer, beginning in fall 2024, a minor in Japanese; master's degree programs in Rehabilitation Science and Public Health (4+1 program), and certificates in Health Equity; Social, Emotional, and Behavioral Wellbeing; and Organizational Leadership.
  • The addition of these academic programs reflects Arcadia's commitment to providing students with a customized education that features interdisciplinary coursework and hands-on learning opportunities.
  • "These upcoming academic programs allow students even more options to earn degrees at Arcadia University, while preparing them for sustained career success," said Jeff Rutenbeck, provost and senior vice president for Academic Affairs at Arcadia University.
  • The programs continue with Arcadia's focus on preparing students for career success: 97 percent of recent Arcadia students secured jobs or graduate program placements within 6 to 9 months of earning their degrees.

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORS

Retrieved on: 
Mardi, février 13, 2024
Acquisition, Diabetes, Senior, Medtronic, Doctor of Philosophy, Computer science, Science Publishing Group, Marketing, US FDA, Growth, MBA, University, Mathematics, Engineering, Software engineering, Fresenius (company), Medtech, Patient, Development, Korea Exchange, Management

“I can think of no better person to lead our Board during this exciting and pivotal time for Glucotrack,” said Andrew Sycoff, member of the Board of Directors.

Key Points: 
  • “I can think of no better person to lead our Board during this exciting and pivotal time for Glucotrack,” said Andrew Sycoff, member of the Board of Directors.
  • “I am honored to take on this important role,” said Mr. Malavé, who has served on the Glucotrack Board since 2021.
  • “Glucotrack has an innovative and compelling technology that will address unmet needs and expand patient choice in the diabetes market.
  • He has been an incredible champion of Glucotrack’s vision throughout his entire tenure on our Board,” said Paul V. Goode, PhD, President & CEO of Glucotrack.

Safer Internet Day 2024: Yubo Supports the UK Safer Internet Centre, Joining Forces to Poll UK Gen Z about Emerging Technologies, Online Safety

Retrieved on: 
Mardi, février 6, 2024
Online, Partnership, Internet, Policy, Parent, Research, Feedback, User experience, Government, Safety, Science Publishing Group, Home, Ageing, Organic, Generation Z, DSIT, Gen, Privacy, Yubo, Department for Education, Childnet, Insafe, Conference, Safer, UKSIC, Online shopping

"Safer Internet Day provides the best opportunity in the year to promote safe and responsible use of technology.

Key Points: 
  • "Safer Internet Day provides the best opportunity in the year to promote safe and responsible use of technology.
  • UKSIC's Safer Internet Day 2024 research generated similar findings to the poll conducted among Yubo users.
  • The UK Safer Internet Centre will host today the Safer Internet Day Virtual Youth Conference, from 1:30 p.m. to 3 p.m. GMT.
  • The results of the Yubo-UK Safer Internet Centre Safer Internet Day 2024 poll can be accessed via the Yubo blog .